In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rebuilding Big Pharma R&D: An Interview With GSK’s Ian Tomlinson

Executive Summary

GlaxoSmithKline’s DPU model is industry’s most radical attempt to apply the lessons – and the pressures – of working in small biotech environments. BD and biopharma head Ian Tomlinson discusses what went wrong, and what GSK thinks it’s now doing right.

You may also be interested in...



J.P. Morgan Notebook: Thursday, January 16

News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.

Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings

More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.

How GSK Is Driving Early Stage Research In Its DPUs

Most of GlaxoSmithKline's early stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel